Canada Life’s Inhibrx, Inc. Common Stock INBX Stock Holding History

Canada Life’s Portfolio INBX Stock Details INBX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,910	Closed	-$102K	–	2159
2024 Q1	$102K	Hold	2,910	–	–	﹤0.01%	1924
2023 Q4	$110K	Buy	2,910 +1,711	+143%	+$36.7K	﹤0.01%	1926
2023 Q3	$22K	Hold	1,199	–	–	﹤0.01%	2117
2023 Q2	$31K	Hold	1,199	–	–	﹤0.01%	2074
2023 Q1	$23K	Hold	1,199	–	–	﹤0.01%	2190
2022 Q4	$30K	Buy	1,199 +537	+81%	+$15.8K	﹤0.01%	2182
2022 Q3	$12K	Hold	662	–	–	﹤0.01%	2329
2022 Q2	$8K	Hold	662	–	–	﹤0.01%	2394
2022 Q1	$16K	Hold	662	–	–	﹤0.01%	2392
2021 Q4	$29K	Hold	662	–	–	﹤0.01%	2307
2021 Q3	$22K	Hold	662	–	–	﹤0.01%	2416
2021 Q2	$18K	Hold	662	–	–	﹤0.01%	2504
2021 Q1	$13K	Hold	662	–	–	﹤0.01%	2552
2020 Q4	$22K	Buy	+662	New	+$17.6K	﹤0.01%	2526

Other funds holding INBX

DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Canada Life's INBX Position: Q2 2024 in Review

Canada Life sold out of Inhibrx, Inc. Common Stock (INBX) in Q2 2024, closing a stake of 2,910 shares — an estimated $102K sold.

Canada Life first reported a position in INBX in Q4 2020 and held it in 14 quarters. The position peaked at $110K in Q4 2023. 2 funds tracked by Wall St. Rank hold INBX as of Q2 2024.

Canada Life reported no remaining Inhibrx, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Canada Life sold 2,910 Inhibrx, Inc. Common Stock shares in Q2 2024, an estimated $102K.
Canada Life first reported a position in Inhibrx, Inc. Common Stock in Q4 2020 and held it in 14 quarters.
Canada Life's Inhibrx, Inc. Common Stock position peaked at $110K in Q4 2023.
2 funds tracked by Wall St. Rank held Inhibrx, Inc. Common Stock as of Q2 2024.

Based on Canada Life's 13F filing for Q2 2024, filed 12 Aug 2024.